Entering into Strategic partnership with Roche Pharma France

Arvato will thus become the new supply chain service provider for Roche Pharma France, a major healthcare player in France. As part of the agreement that has now been signed, Arvato will in future handle warehousing and fulfillment as well as the distribution of pharmaceutical products for Roche Pharma throughout France, including the French overseas territories.

"We were looking for a reliable logistics partner who could guarantee our high standards in the supply chain and our quality standards for patient care at all times," says Gwenaelle Rouillon, Head of logistics for Roche Pharma France. Another important criterion was innovation competence, an aspect that both Arvato and Roche Pharma France see as a key strategic segment. Gwenaelle Rouillon: "In Arvato, we have found a partner who can support us in the further development of our supply chains with its logistics and healthcare expertise and innovative processes." Arvato Supply Chain Solutions was able to convince with a complete solution that covers all pharmaceutical logistics requirements in the two required temperature ranges ambient and cold. "We are very pleased to have won Roche Pharma as a customer and partner. During the implementation of the project, it has already become clear that corporate culture and vision of both companies fit together well – this confirms the partnership approach of the cooperation," says Nicolas Virmoux, General Manager Healthcare at Arvato Supply Chain Solutions, France.

Arvato offers its services at the site in Chanteloup-en-Brie, east of Paris. "Roche Pharma France is not only an important partner for us. The collaboration is at the same time an important step in achieving our strategic goal of becoming one of the two largest healthcare providers in France and setting the benchmark for order-to-cash processes," Nicolas Virmoux explains. To this end, Arvato Supply Chain Solutions has recently invested significantly and, for example, equipped the Chanteloup-en-Brie site with state-of-the-art automation technology for the current requirements in the healthcare business. Nicolas Virmoux: "As the second largest healthcare market in Europe, France still offers a lot of potential. We want to further develop this potential through complete solutions and the high quality of our services in strategic partnerships, such as the one we are now with Roche."

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.